CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Rituximab +13 moredrug
Likely dose
Rituximab 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00450801
NCT00450801Phase 2Completed

Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma

University of Miami·interventional·Posted Mar 22, 2007·Updated Nov 10, 2015

In Brief

A Phase 2 clinical trial evaluating Rituximab, Cyclophosphamide, and 12 other interventions for Lymphoma. Completed, enrolled 22 participants across 1 site.

Detailed Summary

RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works in treating patients with previously untreated mantle cell lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 22, 2007
Enrollment StartApr 1, 2004
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 19.3 years ago

Interventions

Rituximabdrug

Rituximab 375 mg/m2 IV, Days 1 of all cycles

Cyclophosphamidedrug

Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.

Cytarabinedrug

Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.

Doxorubicindrug

Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3

Etoposidedrug

Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4

Ifosfamidedrug

Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4

Leucovorindrug

Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.

Methotrexatedrug

Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.

Thalidomidedrug

Maintenance therapy.

Vincristinedrug

Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.

Mesnadrug

Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4

Filgrastim (G-CSF)drug

G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)

Granisetrondrug

Granisetron 1 mg IV on Day 1, Cycle 1 and 3

Decadrondrug

Decadron 10 mg IV on Day 1, Cycles 1 and 3